Drugs / 68Ga-DOTA-Bombesin
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02440308 | Apr → Jun 2015 | prostate carcinoma | Stanford University | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 68Ga-DOTA-Bombesin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02440308 ↗ |
| Modality | Diagnostic / imaging agent | “This clinical trial studies the use of gallium-68 (68Ga)-DOTA-Bombesin as the imaging agent for positron emission tomography (PET)/magnetic resonance imaging (MRI)” NCT02440308 ↗ |
| Route | Intravenous | “68Ga-DOTA-Bombesin is administered intravenously (IV)” NCT02440308 ↗ |